Skip to main content

Infliximab treatment for rheumatic disease: clinical and radiological efficacy.

Publication ,  Journal Article
St Clair, EW
Published in: Ann Rheum Dis
November 2002

Infliximab is a chimeric anti-tumour necrosis factor alpha (TNFalpha) monoclonal antibody with high affinity and binding specificity for human TNFalpha. Results from several well designed, controlled clinical trials show repeated infusions of infliximab with concomitant methotrexate (MTX) treatment can reduce the signs and symptoms of rheumatoid arthritis (RA). This combination of infliximab and MTX also slows the radiological progression of joint damage, decreases functional disability, and improves qualify of life. These remarkably positive results have led to the investigation of infliximab treatment for other rheumatic diseases. Recently, controlled studies have shown treatment with infliximab can benefit patients with active spondyloarthropathy. TNFalpha has fast become an important therapeutic target in rheumatology.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Rheum Dis

DOI

ISSN

0003-4967

Publication Date

November 2002

Volume

61 Suppl 2

Issue

Suppl 2

Start / End Page

ii67 / ii69

Location

England

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Treatment Outcome
  • Spondylitis, Ankylosing
  • Rheumatic Diseases
  • Radiography
  • Infliximab
  • Humans
  • Arthritis, Rheumatoid
  • Arthritis, Psoriatic
  • Arthritis & Rheumatology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
St Clair, E. W. (2002). Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis, 61 Suppl 2(Suppl 2), ii67–ii69. https://doi.org/10.1136/ard.61.suppl_2.ii67
St Clair, E. W. “Infliximab treatment for rheumatic disease: clinical and radiological efficacy.Ann Rheum Dis 61 Suppl 2, no. Suppl 2 (November 2002): ii67–69. https://doi.org/10.1136/ard.61.suppl_2.ii67.
St Clair EW. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii67–9.
St Clair, E. W. “Infliximab treatment for rheumatic disease: clinical and radiological efficacy.Ann Rheum Dis, vol. 61 Suppl 2, no. Suppl 2, Nov. 2002, pp. ii67–69. Pubmed, doi:10.1136/ard.61.suppl_2.ii67.
St Clair EW. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii67–ii69.

Published In

Ann Rheum Dis

DOI

ISSN

0003-4967

Publication Date

November 2002

Volume

61 Suppl 2

Issue

Suppl 2

Start / End Page

ii67 / ii69

Location

England

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Treatment Outcome
  • Spondylitis, Ankylosing
  • Rheumatic Diseases
  • Radiography
  • Infliximab
  • Humans
  • Arthritis, Rheumatoid
  • Arthritis, Psoriatic
  • Arthritis & Rheumatology